16 Newly Overvalued Stocks this Month

Novartis and Airbus Group are among the stocks now rated as expensive.

Novartis global healthcare company headquarters.
Cristina Arias/Cover via Getty

Once a month, we screen the Europe-listed stocks under Morningstar’s coverage for newly overvalued names—those whose prices have just climbed into ranges warranting 1- or 2-star

Morningstar Ratings
. Over the past month, 16 stocks saw their ratings change to 2 stars, while three joined the seven Europe-listed names in 1-star territory.

The five new 2-star European stocks with the largest market capitalization are:

  • Novartis NOVN
  • Airbus Group AIR
  • Banco Bilbao Vizcaya Argentaria BBVA
  • Zurich Insurance Group ZURN
  • Barclays BARC

The three new 1-star European stocks, ordered by market capitalization, are:

The full list of new 2-star stocks can be found at the bottom of this story. All returns in this article are reported in the stock’s base currency and all data is sourced from Morningstar Direct.

What Is the Morningstar Rating for Stocks?

The Morningstar Rating can help investors identify stocks that are truly undervalued or overvalued, cutting through the market noise. The rating is determined by three factors: a stock’s price, its

fair value estimate
—Morningstar’s estimate of its intrinsic worth—and its
Uncertainty Rating
, which captures the range of potential outcomes for that estimate. Stocks rated 4 or 5 stars are considered undervalued, those rated 3 stars are fairly valued, and the ones rated 1 or 2 stars are considered overvalued.

The Latest Stock Valuation Changes

The Morningstar Europe Index rose 1.49% over the past month as of July 14, leaving the overall European stock market slightly undervalued, hovering at a 3% discount to its fair value estimate on a market cap-weighted basis.

Of the 316 Europe-listed stocks covered by Morningstar analysts:

  • 37% are undervalued, 42% are fairly valued, and 20% are overvalued.
  • Nine are newly undervalued.
  • 16 are newly overvalued.
  • Three moved from a 2-star rating to a 1-star rating.
  • Four moved from a 1-star rating to a 2-star rating.
  • Among the newly overvalued stocks, zero jumped from a 3-star rating to a 1-star rating.
  • Seven are no longer overvalued.

Metrics for This Month’s New 2-Star Stocks

Novartis NOVN

  • Morningstar Rating: ★★
  • Fair Value Estimate: CHF 109
  • Uncertainty Rating: Medium

Following a 0.28% gain over the past month, drug manufacturer Novartis saw its Morningstar Rating move to 2 stars from 3. Novartis has gained 1.78% over the past three months and 30.80% over the past year. The large-core stock has a wide economic moat. Novartis is trading at a 12% premium to its fair value estimate of CHF 109, with an Uncertainty Rating of Medium.

Airbus Group AIR

  • Morningstar Rating: ★★
  • Fair Value Estimate: EUR 180
  • Uncertainty Rating: Medium

Aerospace and defense company Airbus Group climbed 9.29% over the past month, bumping its Morningstar Rating to 2 stars from 3. The company’s stock is up 15.55% over the past three months and 9.08% over the past year. The stock’s price is 9% above its fair value estimate of EUR 180, with an Uncertainty Rating of Medium. The large-growth stock has a wide economic moat.

Banco Bilbao Vizcaya Argentaria BBVA

  • Morningstar Rating: ★★
  • Fair Value Estimate: EUR 18
  • Uncertainty Rating: High

Following a 12.34% gain over the past month, diversified bank Banco Bilbao Vizcaya Argentaria saw its Morningstar Rating move to 2 stars from 3. Banco Bilbao Vizcaya Argentaria has gained 12.46% over the past three months and 82.19% over the past year. The large-core stock has a narrow economic moat. Banco Bilbao Vizcaya Argentaria is trading at a 25% premium to its fair value estimate of EUR 18, with an Uncertainty Rating of High.

Zurich Insurance Group ZURN

  • Morningstar Rating: ★★
  • Fair Value Estimate: CHF 550
  • Uncertainty Rating: Low

Diversified insurance firm Zurich Insurance Group gained 8.83% over the past month, shifting its Morningstar Rating to 2 stars from 3. Zurich Insurance Group has climbed 11.04% over the past three months and 16.83% over the past year. The stock is trading at a 12% premium to its fair value estimate of CHF 550, with an Uncertainty Rating of Low. Zurich Insurance Group is a large-core company with a narrow economic moat.

Barclays BARC

  • Morningstar Rating: ★★
  • Fair Value Estimate: GBX 435
  • Uncertainty Rating: High

Following a 9.95% gain over the past month, diversified bank Barclays saw its Morningstar Rating move to 2 stars from 3. Barclays has gained 17.37% over the past three months and 54.21% over the past year. The large-core stock has no economic moat. Barclays is trading at a 20% premium to its fair value estimate of GBX 435, with an Uncertainty Rating of High.

Metrics for This Month’s New 1-Star Stocks

DHL Group DHL

  • Morningstar Rating: ★
  • Fair Value Estimate: EUR 40
  • Uncertainty Rating: Medium

Integrated freight and logistics firm DHL Group gained 10.63% over the past month, shifting its Morningstar Rating to 1 star from 2. DHL Group has climbed 22.09% over the past three months and 53.14% over the past year. The stock is trading at a 43% premium to its fair value estimate of EUR 40, with an Uncertainty Rating of Medium. DHL Group is a large-value company with a narrow economic moat.

Sandvik SAND

  • Morningstar Rating: ★
  • Fair Value Estimate: SEK 245
  • Uncertainty Rating: High

Following a 3.22% gain over the past month, specialty industrial machinery firm Sandvik saw its Morningstar Rating move to 1 star from 2. Sandvik has lost 0.66% over the past three months and has gained 74.26% over the past year. The large-growth stock has a wide economic moat. Sandvik is trading at a 60% premium to its fair value estimate of SEK 245, with an Uncertainty Rating of High.

Salvatore Ferragamo SFER

  • Morningstar Rating: ★
  • Fair Value Estimate: EUR 6.40
  • Uncertainty Rating: High

Luxury goods firm Salvatore Ferragamo climbed 5.77% over the past month, bumping its Morningstar Rating to 1 star from 2. The company’s stock is up 30.32% over the past three months and 95.92% over the past year. The stock’s price is 57% above its fair value estimate of EUR 6.40, with an Uncertainty Rating of High. The small-growth stock has no economic moat.

This article was generated with the help of automation and reviewed by Morningstar editors. Learn more about Morningstar's use of automation

The author or authors do not own shares in any securities mentioned in this article. Find out about Morningstar's editorial policies.